Case of Fonsecaea nubica chromoblastomycosis from the French territory of Mayotte

References

1. Alvarez E., Garcia‐Hermoso D., Sutton D.A., Cano J.F., Stchigel A.M., Hoinard D., Fothergill A.W., Rinaldi M.G., Dromer F., Guarro J. ( 2010). Molecular phylogeny and proposal of two new species of the emerging pathogenic fungus Saksenaea . J Clin Microbiol 48:4410–4416 [CrossRef]
   [Google Scholar]
2. Ameen M. ( 2009). Chromoblastomycosis: clinical presentation and management. Clin Exp Dermatol 34:849–854 [CrossRef]
   [Google Scholar]
3. Bonifaz A., Carrasco‐Gerard E., Saúl A. ( 2001). Chromoblastomycosis: clinical and mycologic experience of 51 cases. Mycoses 44:1–7 [CrossRef]
   [Google Scholar]
4. Gupta A.K., Taborda P.R., Sanzovo A.D. ( 2002). Alternate week and combination itraconazole and terbinafine therapy for chromoblastomycosis caused by Fonsecaea pedrosoi in Brazil. Med Mycol 40:529–534 [CrossRef]
   [Google Scholar]
5. López Martínez R., Méndez Tovar L.J. ( 2007). Chromoblastomycosis. Clin Dermatol 25:188–194 [CrossRef]
   [Google Scholar]
6. Najafzadeh M.J., Sun J., Vicente V., Xi L., van den Ende A.H.G.G., de Hoog G.S. ( 2010). Fonsecaea nubica sp. nov, a new agent of human chromoblastomycosis revealed using molecular data. Med Mycol 48:800–806 [CrossRef]
   [Google Scholar]
7. Najafzadeh M.J., Sun J., Vicente V.A., Klaassen C.H.W., Bonifaz A., van den Ende A.H.G.G., Menken S.B.J., Sybren de Hoog G. ( 2011). Molecular epidemiology of Fonsecaea species. Emerg Infect Dis 17:464–469 [CrossRef]
   [Google Scholar]
8. Queiroz‐Telles F., McGinnis M.R., Salkin I., Graybill J.R. ( 2003). Subcutaneous mycoses. Infect Dis Clin North Am 17:59–85 viii [CrossRef]
   [Google Scholar]
9. Queiroz‐Telles F., Esterre P., Perez‐Blanco M., Vitale R.G., Salgado C.G., Bonifaz A. ( 2009). Chromoblastomycosis: an overview of clinical manifestations, diagnosis and treatment. Med Mycol 47:3–15 [CrossRef]
   [Google Scholar]
10. Slesak G., Inthalad S., Strobel M., Marschal M., Hall M.J., Newton P.N. ( 2011). Chromoblastomycosis after a leech bite complicated by myiasis: a case report. BMC Infect Dis 11:14 [CrossRef]
    [Google Scholar]
11. Subcommittee on Antifungal Susceptibility Testing (AFST) of the ESCMID European Committee for Antimicrobial Susceptibility Testing (EUCAST)( 2008). EUCAST technical note on the method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia‐forming moulds. Clin Microbiol Infect 14:982–984 [CrossRef]
    [Google Scholar]
12. Sun J., Najafzadeh M.J., Gerrits van den Ende A.H.G., Vicente V.A., Feng P., Xi L., De Hoog G.S. ( 2012). Molecular characterization of pathogenic members of the genus Fonsecaea using multilocus analysis. PLoS One 7
    [Google Scholar]
13. Ungpakorn R., Reangchainam S. ( 2006). Pulse itraconazole 400 mg daily in the treatment of chromoblastomycosis. Clin Exp Dermatol 31:245–247 [CrossRef]
    [Google Scholar]